Recent data also links inhibition of GCPII to improvement of cognitive deficits in models of traumatic brain injury (Feng et al., 2011; Gurkoff et al., 2013; Gao et al., 2015; Ji et al., 2023), multiple sclerosis (Rahn et al., 2012; Hollinger et al., 2016; Hollinger et al., 2022), schizophrenia (Janczura et al., 2013; Olszewski et al., 2012; Takatsu et al., 2011), and aging (Olszewski et al., 2017; Datta et al., 2021; Bathla et al., 2023; Yang et al., 2022). This evidence concerns the gene FOLH1 and Cognitive impairment.